Progress of GlycoMimetics’ Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology

GAITHERSBURG, MD, December 13, 2011 – GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that its collaborators delivered three oral presentations at the 2011 Annual Meeting of the American Society of Hematology (ASH). The presentations highlighted data on GMI-1070, GMI’s lead investigational compound for the treatment of vaso-occlusive crises associated sickle cell disease which is under an exclusive worldwide licensing agreement with Pfizer, Inc. (NYSE:PFE), as well as data from a novel family of compounds being developed to treat AML and other cancers.

GMI’s novel antagonists targeting E-selectin and CXCR4 were described in a presentation entitled “Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc/- Xenograft and Confer Susceptibility to Cytarabine.” As noted in the abstract from the presentation, “By 15 days post treatment with the combination of GMI-1257 and cytarabine, human CD34+ leukemia cells were largely depleted from the bone marrow (by 90%) compared to treatment with cytarabine alone. These novel dual inhibitors of E-selectin and CXCR4 effectively mobilize leukemia from the marrow and reduce the bone marrow burden of AML in combination with chemotherapy.”

Data from GMI-1070, now in Phase 2 clinical trials in sickle cell crisis, were discussed in presentations titled “Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070,” and “Pan-Selectin Antagonist, GMI-1070 Decreases Venous Thrombosis in a Mouse Model.” Abstracts summarizing these findings, which support continued research, can be viewed online at http://ash.confex.com/ash/2011/webprogram/start.html.

“We are very pleased that abstracts highlighting data from our novel compounds were selected for oral presentations at the ASH meeting,” said Rachel King, Chief Executive Officer, GlycoMimetics. “We continue to make significant progress with our pipeline programs. Data from GMI-1070 provide additional support for testing the drug candidate in sickle cell crisis, and the Phase 2 trial is now underway. We are also excited about the preclinical results with other compounds in AML, which suggest that these drug candidates may have a novel mechanism of action for treatment of hematologic malignancies.”

About GlycoMimetics, Inc.

GlycoMimetics is a privately held biotechnology company that capitalizes on advances in the field of glycobiology. The company uses rational design of small molecule drugs that mimic the functions of bioactive carbohydrates to develop new drug candidates. The company's initial focus is on therapeutics to treat inflammation, cancer, and infectious diseases. For additional information, please visit the company's web site: http://www.glycomimetics.com.
MEDIA CONTACT
Brian Hahn
Phone: 240-243-1207
Email Address: bhahn@glycomimetics.com